Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction	Viatris Innovation GmbH / IQVIA	Ongoing	(ACT-246475) is a 2-phenyl-pyrimidine derivative selatogrel	3	ID-076A301 / SOS-AMI	King Faisal Specialist Hospital and Research Center (Riyadh).
A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma	Celgene Corporation / Balsam Clinical Research	Ongoing	Golcadomide / Rituximab	3	CA0731003	King Faisal Specialist Hospital and Research Center (Riyadh)
Randomized, Multicenter, Multinational, Double-Blind Study to Compare the Pharmacokinetics, Efficacy, Safety and Immunogenicity of MB12 (Proposed PembrolizumabBiosimilar) versus Keytruda® in Combination with Chemotherapy for the Treatment of Patients with Advanced Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (BENITO Study)	mAbxience Research SLU / Balsam	Ongoing	MB12 (proposed pembrolizumab biosimilar)	3	MB12-C-02-24	King Saud University Medical City (Riyadh)
A randomized, double-blind, placebo-controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of mucus plugging and other lung imaging parameters in patients with chronic obstructive pulmonary disease	Arabia trading limited / Arabmed	Ongoing	Dupixent	4	LPS18583	King Khalid University Hospital (Riyadh).
Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Participants with Cholestatic Pruritus	Mirum Pharmaceuticals, Inc. / CTI	Ongoing	Maralixibat	3	MRX-802	King Faisal Specialist Hospital and Research Center (Riyadh).
A low-interventional study to evaluate long-term effectiveness of real-world prophylactic treatment with efanesoctocog alfa on joint health in people with haemophilia A (ALTITUDE)	Swedish Orphan Biovitrum AB/ Balsam	Ongoing	Efanesoctocog alfa	4	BIVV001005	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants with Heart Failure due to Systemic Left Ventricular Systolic Dysfunction (VALOR)	Merck Sharp & Dohme KSA GmbH	Ongoing	Vericiguat	2	NCT0571408	King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh)
Immune Ablation Therapy Followed by Autologous Hematopoietic Stem Cell Transplantation for The Treatment of Multiple Sclerosis: A Single-Arm Study	King Faisal Specialist Hospital and Research Center (Riyadh)	Ongoing	Busulfan BOS / Cyclophosphamide/ Thymoglobulin	2	2251066	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency (Harmony)	Travere Therapeutics, Inc. / CTI	Ongoing	Pegtibatinase	3	TVTX-TVT058-301	King Faisal Specialist Hospital and Research Center (Riyadh) ,King Abdulaziz Medical City NG (Riyadh)
Randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4- related disease	Sanofi / Arab Med	Ongoing	Rilzabrutinib	3	EFC17359	King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh)